<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alena Moerman</style></author><author><style face="normal" font="default" size="100%">Kris Vernelen</style></author><author><style face="normal" font="default" size="100%">Bernard China</style></author><author><style face="normal" font="default" size="100%">Arnaud Capron</style></author><author><style face="normal" font="default" size="100%">Dorien Van Den Bossche</style></author><author><style face="normal" font="default" size="100%">Joachim Mariën</style></author><author><style face="normal" font="default" size="100%">Ariën, Kevin K</style></author><author><style face="normal" font="default" size="100%">Van Acker, Jos</style></author><author><style face="normal" font="default" size="100%">Delforge, Marie-Luce</style></author><author><style face="normal" font="default" size="100%">Marijke Reynders</style></author><author><style face="normal" font="default" size="100%">An Boel</style></author><author><style face="normal" font="default" size="100%">Melissa Depypere</style></author><author><style face="normal" font="default" size="100%">Natasja Van Gasse</style></author><author><style face="normal" font="default" size="100%">Sara Vijgen</style></author><author><style face="normal" font="default" size="100%">Jonathan Brauner</style></author><author><style face="normal" font="default" size="100%">Barbara Dujardin</style></author><author><style face="normal" font="default" size="100%">Padalko, Elizaveta</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Importance of anti-SARS-CoV-2 assay antigenic composition as revealed by the results of the Belgian external quality assessment (EQA) scheme.</style></title><secondary-title><style face="normal" font="default" size="100%">Diagn Microbiol Infect Dis</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Antigens, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Coronavirus Nucleocapsid Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 Serological Testing</style></keyword><keyword><style  face="normal" font="default" size="100%">Diagnostic Tests, Routine</style></keyword><keyword><style  face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin A</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin M</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Phosphoproteins</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style  face="normal" font="default" size="100%">Spike Glycoprotein, Coronavirus</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Feb</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">102</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We report on sample IS/17575 since it generated highly divergent results in the Belgian SARS-CoV-2 serology external quality assessment scheme. Sample IS/17575 was serum originating from a 30 years old male patient. 124 diagnostic laboratories analysed this sample. A total of 168 results was returned (including 5 doubles). Overall, 38 were positive. All tests against S1 were positive except the Euroimmun IgG ELISA and the Ortho clinical Diagnostics VITROS IgG CLIA. All tests against S1/S2 (Liaison, Diasorin) resulted in a signal above cutoff. Assays against RBD, mostly generate a negative result. An exception are the Wantai SARS-CoV-2 ELISA's. All tests targeting N protein were negative. The survey shows, when &amp;gt;6 months post-infection, assays targeting at least S1, and preferably S1 combined with S2, are the most sensitive. This finding accentuates the necessity of external quality assessment schedules and importance of antigenic composition of serologic SARS-CoV-2 assays.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue></record></records></xml>